Overview

Different Immunosuppressive Treatment in iMN

Status:
Recruiting

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)

Phase:

Phase 3

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Cyclophosphamide
Prednisone
Rituximab